A neuroendocrine biomarker revolution from monoanalyte to multianalyte biomarkers in non-functioning gastro-entero-pancreatic neuroendocrine neoplasms

被引：1

作者：

Hoff, Camilla O. ^{[1
]}

Manzi, Joao ^{[1
]}

Ferreira, Raphaella ^{[2
]}

Chauhan, Aman ^{[3
]}

Housein, Peter ^{[3
]}

Merchant, Nipun ^{[3
]}

Livingstone, Alan ^{[3
]}

Vianna, Rodrigo ^{[2
]}

Abreu, Phillipe ^{[4
]}

机构：

[1] Univ Sao Paulo, Sao Paulo Med Sch, Sao Paulo, Brazil

[2] Univ Miami, Jackson Mem Hosp, Miami Transplant Inst, Miami, FL USA

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Univ Colorado, Div Transplant Surg, Anschutz Med Campus, Aurora, CO USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2024年 / 203卷

关键词：

Liver transplant; Oncology; Neuroendocrine tumors; Biomarkers; CIRCULATING TUMOR-CELLS; NEURON-SPECIFIC ENOLASE; PROGRESSION-FREE SURVIVAL; PLASMA CHROMOGRANIN-A; PROGNOSTIC MARKERS; PANCREATIC-CANCER; FOLLOW-UP; MICRORNA EXPRESSION; CLINICAL UTILITY; HIGH-GRADE;

D O I：

10.1016/j.critrevonc.2024.104460

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neuroendocrine neoplasms (NENs) arise from neuroendocrine cells in a wide variety of organs. One of the most affected disease sites is the gastrointestinal system, which originates the gastro-entero-pancreatic NENs (GEPNENs), a heterogenous group of malignancies that are rapidly increasing in incidence. These tumors can be functioning, with secretory activity leading to identifiable clinical syndromes, or non-functioning, with no secretory activity but with local symptoms of tumor growth and metastasis. A limitation in biomarkers is a crucial unmet need in non-secretory NEN management, as clinical decision-making is made more difficult by obstacles in tumor classification, prognostic evaluation, assessment of treatment response and surveillance. The objective of this review is to present existing and novel biomarkers for NENs that can function as prognostic factors and monitor disease progression or regression longitudinally, with a special emphasis on innovative research into novel multianalyte biomarkers.

引用

页数：12

共 121 条

[1] Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations [J].

Abdel-Rahman, Omar .

TUMOR BIOLOGY, 2014, 35 (11) :10615-10625

[2] Sensitivity and Specificity of the NETest: A Validation Study [J].

Al-Toubah, Taymeyah ;

Cives, Mauro ;

Valone, Tiffany ;

Blue, Kirsten ;

Strosberg, Jonathan .

NEUROENDOCRINOLOGY, 2021, 111 (06) :580-585

[3] Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition [J].

Allen, Elizabeth ;

Walters, Ian B. ;

Hanahan, Douglas .

CLINICAL CANCER RESEARCH, 2011, 17 (16) :5299-5310

[4] miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival [J].

Arvidsson, Yvonne ;

Rehammar, Anna ;

Bergstrom, Anders ;

Andersson, Ellinor ;

Altiparmak, Gulay ;

Sward, Christina ;

Wangberg, Bo ;

Kristiansson, Erik ;

Nilsson, Ola .

MODERN PATHOLOGY, 2018, 31 (08) :1302-1317

[5] The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms [J].

Basturk, Olca ;

Yang, Zhaohai ;

Tang, Laura H. ;

Hruban, Ralph H. ;

Adsay, Volkan ;

McCall, Chad M. ;

Krasinskas, Alyssa M. ;

Jang, Kee-Taek ;

Frankel, Wendy L. ;

Balci, Serdar ;

Sigel, Carlie ;

Klimstra, David S. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (05) :683-690

[6] Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors [J].

Beyens, Matthias ;

Vandamme, Timon ;

Peeters, Marc ;

Van Camp, Guy ;

Op de Beeck, Ken .

[7] Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors [J].

Bodei, L. ;

Kidd, M. ;

Modlin, I. M. ;

Severi, S. ;

Drozdov, I. ;

Nicolini, S. ;

Kwekkeboom, D. J. ;

Krenning, E. P. ;

Baum, R. P. ;

Paganelli, G. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (05) :839-851

[8] PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy [J].

Bodei, Lisa ;

Kidd, Mark S. ;

Singh, Aviral ;

van der Zwan, Wouter A. ;

Severi, Stefano ;

Drozdov, Ignat A. ;

Cwikla, Jaroslaw ;

Baum, Richard P. ;

Kwekkeboom, Dik J. ;

Paganelli, Giovanni ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (07) :1155-1169

[9] The Status of Neuroendocrine Tumor Imaging: From Darkness to Light? [J].

Bodei, Lisa ;

Sundin, Anders ;

Kidd, Mark ;

Prasad, Vikas ;

Modlin, Irvin M. .

NEUROENDOCRINOLOGY, 2015, 101 (01) :1-17

[10] Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor [J].

Boesch, Florian ;

Altendorf-Hofmann, Annelore ;

Jacob, Sven ;

Auernhammer, Christoph J. ;

Spitzweg, Christine ;

Boeck, Stefan ;

Schubert-Fritschle, Gabriele ;

Werner, Jens ;

Kirchner, Thomas ;

Angele, Martin K. ;

Knoesel, Thomas .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) :1-12

← 1 2 3 4 5 6 7 8 9 10 →